---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-036339"
form_type: "8-K"
ticker: "GALT"
cik: "0001133416"
company_name: "GALECTIN THERAPEUTICS INC"
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T04:52:07.692869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Galectin Therapeutics reports positive DSMB outcome for NAVIGATE study of belapectin in NASH cirrhosis

## Summary
- Second DSMB meeting recommends study continue as designed without modifications.
- NAVIGATE is a seamless adaptive Phase 2b/3 trial of belapectin for primary prevention of esophageal varices in NASH cirrhosis.
- Enrollment: 258 patients randomized; 74 in screening; full enrollment expected around year-end 2022.
- DSMB confirms belapectin appears safe and well tolerated in fragile cirrhotic patients.

## SEC filing metadata
- accession: 0001140361-22-036339
- form_type: 8-K
- ticker: GALT
- cik: 0001133416
- company_name: GALECTIN THERAPEUTICS INC
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/0001140361-22-036339-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133416/000114036122036339/brhc10042729_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-036339
- JSON: https://secwatch.observer/filing/0001140361-22-036339.json
- Plain text: https://secwatch.observer/filing/0001140361-22-036339.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.